ViaCyte to Present at Healthcare Events in October

SAN DIEGO, October 11, 2016 ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced four presentations at upcoming healthcare events.  The presentations will highlight work related to the two product candidates that ViaCyte is actively developing.

Details of the presentations are as follows:

Event:                BioJapan 2016
Speaker:           Dr. Mark Zimmerman, Vice President, Strategy & Business Development
Presentation:   Front-line R&D of Regenerative Medicine Products
Date/Time:       October 14, 3:00 pm JST
Location:          Annex Hall F205/F206, Pacifico Yokohama, Yokohama, Kanagawa Prefecture, Japan

Event:               International Stem Cell Initiative: The Origins and Implications of Pluripotent Stem Cell Genetic and Epigenetic Instability at Jackson Labs
Speaker:           Dr. Allan Robins, Senior Vice President, Science & Technology
Date/Time:      October 15, 8:00 am EDT
Location:          Jackson Labs, Bar Harbor, Maine

Event:               2016 BIO Investor Forum
Speaker:           Dr. Paul Laikind, President & CEO
Date/Time:       October 18, 9:30 am PDT
Location:          Elizabethan D, Westin St. Francis, San Francisco, California

Event:               International Conference on Stem Cell Engineering
Speaker:           Dr. Kevin D’Amour, Vice President, Research, & Chief Scientific Officer
Date/Time:       October 25, 2:45 pm EDT
Location:          Toronto Marriott Bloor Yorkville, Ontario, Canada

For more information about ViaCyte’s participation in industry events, please visit:

About ViaCyte

ViaCyte is a privately-held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to reduce the risk of hypoglycemia and diabetes-related complications.  ViaCyte’s product candidates are based on the derivation of pancreatic progenitor cells, which are then implanted in durable and retrievable delivery devices.  Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels.  ViaCyte has two products in development.  The PEC-Direct product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device and is being developed for type 1 diabetes patients that have severe hypoglycemic episodes, extreme glycemic lability, and/or impaired hypoglycemia awareness.  The PEC-Encap (also known as VC-01) product candidate delivers pancreatic progenitor cells in an immunoprotective device and is currently being evaluated in a Phase 1/2 trial in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function.  ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia.  The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.